Bluejay Diagnostics, Inc.
Close on Oct 19, 2026
- Market cap
- $1.45M
- P/E (TTM)
- –
- Dividend yield
- –
About Bluejay Diagnostics
Surgical & Medical Instruments & Apparatus, SIC 3841
Bluejay Diagnostics, Inc. is a medical diagnostics company dedicated to improving patient care in critical healthcare environments, particularly for individuals diagnosed with sepsis. The company is actively developing point-of-care, rapid diagnostic tests that use whole blood samples with its proprietary Symphony technology platform. This platform comprises a specialized centrifugal analyzer and single-use protein detection cartridges designed to measure key biomarkers, with its lead product candidate focused on interleukin-6 testing. Bluejay Diagnostics intends to serve healthcare providers operating in critical care environments, with a particular focus on intensive care units and emergency rooms within acute care facilities.
The company focuses its commercialization plans on large critical care hospital facilities situated across the United States. Its technology relies on cartridge manufacturing and development operations conducted through a partner facility located in Japan. Bluejay Diagnostics maintains its corporate headquarters in Acton, Massachusetts.
Summary of the business section of Bluejay Diagnostics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Bluejay Diagnostics, Inc.
- Founded
- 2015
- Headquarters
- Acton, MA
- Address
- 360 Massachusetts Avenue, Suite 203 01720
- Phone
- (978) 631-0152
- Employees
- 6, Dec 31, 2025
- Industry
- Surgical & Medical Instruments & Apparatus
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Wolf & Company, P.C., Boston, Massachusetts
Stock & identifiers
- Ticker
- BJDX
- Exchange
- Nasdaq
- IPO date
- Nov 12, 2021
- Shares outstanding
- 4M, Aug 7, 2026
- Public float
- $2.57M, Jun 30, 2025
- Filer category
- <br>Emerging growth company
- Stock splits
- 1-for-4 reverse, Mar 6, 2026; 1-for-4 reverse, Jan 29, 2026; 1-for-50 reverse, Mar 31, 2025; 1-for-50 reverse, Nov 18, 2024; 1-for-8 reverse, Aug 14, 2024; 1-for-8 reverse, Jun 20, 2024; 1-for-20 reverse, Aug 14, 2023; 1-for-20 reverse, Jul 24, 2023
- SEC CIK
- 1704287
- CUSIP
- 095633608
- ISIN
- US0956336087
- EIN
- 47-3552922
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Indranil Dey | President and CEO, Director | 40,649 |
| Svetlana Dey | Director | 12,628 |
| Douglas Clark Wurth | Director | 1,121,491 |
| Fred S. Zeidman | Director | 12,500 |
| Donald R. Chase | Director | 12,525 |
Employees
Headcount reported in annual reports
“As of March 2, 2026, we have 6 full-time employees, which includes one executive officer.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Aug 28, 2024 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Mar 4, 2024 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Apr 27, 2023 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Oct 28, 2022 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Nov 12, 2021 | IPO | Initial public offering priced (424B4 prospectus) |
| Nov 5, 2021 | Listing | Registration of securities on an exchange (Form 8-A) |